Mednow Investor Presentation Deck

Strategic Acquisition of InfusiCare Canada and Liver Specialty Group¹ $9.3M¹ Mednow acquires InfusiCare Canada Inc. Adds specialty pharmacy to Mednow's offering, Biologic drugs make up 42% of patented pharmaceutical sales in Canada² • In 2017, 70% of top selling patented pharmaceuticals were biologic drugs, compared to 10% in 2006³ Expands logistical infrastructure in Southwestern Ontario, by increasing more densely populated cities mednow I TSX-V: MNOW I OTC-QB: MDNWF $21.3M¹ Mednow acquires Liver Specialty Group. • Increases specialty pharmacy services and expertise to include hepatology and the treatment of liver disease. • Services over 20,000 patient visits annually both virtually and in-person • In 2020, hepatitis C medications accounted for the third largest class of drug by percentage of public drug spending in Canada² 1. InfusiCare and Liver Specialty Group Revenue from audited statement of operations as of July 31, 2021 2. Government of Canada Market Trends 3. Patented Medicine Prices Review Board Annual Report 2017 0000 38

View entire presentation